Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Logos Global Management LP (CIK 1792126) reported $2.32B across 68 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: ERAS ($222.6M, 9.58%), ABVX ($136.5M, 5.87%), RVMD ($131.1M, 5.64%), IDYA ($111.8M, 4.81%), BNTX ($94.4M, 4.07%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ERAS | ERASCA INC | $222.6M | 9.58% | 12.2M | Added |
| 2 | ABVX | ABIVAX SA | $136.5M | 5.87% | 1.0M | Added |
| 3 | RVMD | REVOLUTION MEDICINES INC | $131.1M | 5.64% | 700,000 | Trimmed |
| 4 | IDYA | IDEAYA BIOSCIENCES INC | $111.8M | 4.81% | 3.0M | Trimmed |
| 5 | BNTX | BIONTECH SE | $94.4M | 4.07% | 1.0M | New |
| 6 | VERA | VERA THERAPEUTICS INC | $94.4M | 4.06% | 2.2M | New |
| 7 | TNGX | TANGO THERAPEUTICS INC | $89.1M | 3.84% | 2.9M | Trimmed |
| 8 | PRAX | PRAXIS PRECISION MEDICINES I | $87.0M | 3.75% | 260,000 | Trimmed |
| 9 | DNTH | DIANTHUS THERAPEUTICS INC | $78.0M | 3.36% | 800,000 | Added |
| 10 | CLDX | CELLDEX THERAPEUTICS INC NEW | $78.1M | 3.36% | 2.1M | Added |
| 11 | CGON | CG ONCOLOGY INC | $71.0M | 3.06% | 1.0M | Added |
| 12 | IRON | DISC MEDICINE INC | $64.0M | 2.76% | 875,000 | Added |
| 13 | MAZE | MAZE THERAPEUTICS INC | $57.7M | 2.49% | 1.9M | Added |
| 14 | DYN | DYNE THERAPEUTICS INC | $56.6M | 2.44% | 2.5M | Added |
| 15 | OCUL | OCULAR THERAPEUTIX INC | $52.0M | 2.24% | 5.3M | Added |
| 16 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $52.1M | 2.24% | 2.7M | Added |
| 17 | DSGN | DESIGN THERAPEUTICS INC | $43.4M | 1.87% | 3.0M | Added |
| 18 | OLMA | OLEMA PHARMACEUTICALS INC | $40.1M | 1.73% | 3.2M | Hold |
| 19 | BLTE | BELITE BIO INC | $38.5M | 1.66% | 250,000 | New |
| 20 | ACHV | ACHIEVE LIFE SCIENCE INC | $35.4M | 1.53% | 5.4M | New |
| 21 | TRVI | TREVI THERAPEUTICS INC | $35.1M | 1.51% | 1.9M | Trimmed |
| 22 | COGT | COGENT BIOSCIENCES INC | $34.8M | 1.50% | 900,000 | New |
| 23 | AVBP | ARRIVENT BIOPHARMA INC | $34.7M | 1.50% | 1.0M | Added |
| 24 | CBIO | CRESCENT BIOPHARMA INC. | $34.2M | 1.47% | 1.9M | Added |
| 25 | CMPS | COMPASS PATHWAYS PLC | $31.8M | 1.37% | 2.2M | New |
Source: SEC Form 13F filings · as of 2026-06-30